Opthea Ltd
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Opthea
Biological Products, (No Diagnostic Substances), SIC 2836
The provided text consists of XBRL data tags, equity plan member identifiers, and financial statement line codes rather than descriptive narrative text. These items indicate that the company operates in biopharmaceutical development with references to Opthea US Inc and Vegenics Pty Ltd, but the excerpt does not disclose specific products, services, segments, or customer groups.
Operational scale, facilities, store counts, and geographic presence are not described in the text. Aside from references to Australian banking entities and an Australian domiciled subsidiary, the document does not state where the company is headquartered or provide details on its physical locations.
Summary of the business section of Opthea's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Opthea Ltd
- Headquarters
- South Yarra, Australia
- Address
- Level 4, 650 Chapel Street 3141
- Phone
- 61 3 9826 0399
- Employees
- 4, Jun 30, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- C3
- Fiscal year ends
- June 30
- Auditor
- Deloitte Touche Tohmatsu, Melbourne, Australia
Stock & identifiers
- Ticker
- CKDXF
- Other tickers
- CYVNY
- Exchange
- OTC
- IPO date
- Oct 19, 2020
- Shares outstanding
- 1.24B, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 1815620
- CUSIP
- 68386J208
- ISIN
- US68386J2087
- LEI
- 549300Q5FMFDLP46SF83
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Opthea's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“As of September 11, 2025, we had 4 full-time employees in our administration department, all located in Australia.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 20, 2025 | Deregistration | Termination of SEC registration (Form 15) |
| Nov 10, 2025 | Delisting | Notice of delisting from exchange (Form 25) |
| Oct 19, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 14, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |